Chronic Pain Relief Now

Call 1-888-E-STIMULATE
Chronic Pain Relief


 Information
Mind and Body
Fibromyalgia
Migraine Pain
Back Pain
Carpal Tunnel
Arthritis Pain
M.D. Surveys
Testimonials
Endorsements
Our Site Map
Prescribing Info
Contact Us
 

Pg. 3

<Previous Page  First Page^  Next Page>

The Treatment of Fibromyalgia with Cranial Electrotherapy Stimulation
Alan S. Lichtbroun, Mei-Ming C. Raicer, Ray B. Smith
 

score could also be computed with a formula given in the POMS user's manual.
Following the pretests, subjects in groups I and II were taught how to use the CES unit, and they were instructed to use it every day for 1 hour over a 3-week period. At the end of that time, they returned to the clinic for posttreatment evaluations as above. Group III subjects were given no CES device, but they were told to return in 3 weeks for retesting.
All subjects were told that those sham-treated and placebo-controlled patients who did not receive treatment during the study would be provided CES treatment after the conclusion of the double-blinded part of the study if they wished. That treatment would be in an open, non-double-blind clinical trial in which each patient would be provided an Alpha-Stim CES unit to use at home, and they would be allowed to adjust the stimulation intensity to maximum comfort level.
During the study, a clinical staff member called each member of groups I and II once a week to check on compliance. It was checked again when subjects came in for final study evaluations.

RESULTS
No differences were found on the 12 pretest measures among the three study groups at the beginning of the study. The question sometimes arises in studies of this kind if the study outcome might be attributed to differences in patient medications in the various study groups. We did not control specifically for that, assuming that the randomization of patients into the three groups would scatter this effect more or less equally across the groups. These results indicate that the assumption was correct.
The double-blind condition depended on the stimulation current being below sensation threshold in most patients so that the patients would not know whether or not

 

they were actually receiving treatment. CES electrodes contain a felt covering that is thoroughly wetted prior to placing it on the patient, and many patients experience the cold covering as stimulation, and they report a feeling of tingling, even after the moistened felt has warmed to skin temperature. Be-cause sham-treated patients have been just as likely to report this sensation as have treated patients in past studies, we did not ask for this information from the patients. After the study, however, four patients volunteered the information that they had felt a tingling sensation from the electrodes during the study. Two were later found to be sham treated and two had received actual treatment.
The double-blind treated group had significant mean gains on tender point score (t = 2.27, p < 0.01), self-rated pain (t = 3.04, p < 0.002), quality of sleep (t = 2.05, p < 0.02), feeling of well-being (t = 1.67, p < 0.05), and quality of life (t = 1.92, p < 0.03). There were 38 degrees of freedom on each analysis. The sham-treated and placebo-controlled groups had no positive gains during the study.
Since subsensation CES at 100 ľA is a very small level of stimula-
 
tion, it was decided also to compare the treated subjects in the double-blind study against those in the poststudy open clinical group who reported having used an intensity of stimulation that was above sensation level.
Only 23 of the 40 control patients opted for actual CES treatment after their participation in the double-blind part of the study. When the test scores of those who came in for the additional treatment were compared with those of the group not asking for additional treatment, no differences were found on their 12 pretest measures except on the self-rated quality of life, in which those requesting treatment had significantly lower scores (t = 2.48, df = 38, p < 0.02).
The four groups that were analyzed are shown in Figure 1, where it can be seen that there was no positive placebo effect among the sham-treated patients on the scores presented. One-tailed analyses were performed to see if the observed mean reductions of the scores among the treated groups were significant.
The open clinical group had significant gains on tender point scores (t = 3.27, p < 0.001), self-rated pain (t = 1.68, p < 0.05), qual-

 

 

<Previous Page  First Page^  Next Page>

Journal of Clinical Rheumatology • Volume 7, Number 2 • April 2001

 

©2006 by
 

Disclaimers-  Alpha-Stim® is manufactured by Electromedical Products International, Inc. (EPI).  Chronic Pain Relief Now.Com and Moeller Medical, LLC are  not associated with EPI except to the extent of acting distributors of the Alpha-Stim® device.  The Alpha-Stim® name and the Alpha-Stim® logo are trademarks of EPI.
United States readers note:
Material on this site is being provided only for educational information and as background material for potential researchers, not for promotional purposes.
Chronic Pain Relief Now.Com and Moeller Medical, LLC express no opinion with regard to representations made herein.  Chronic Pain Relief Now.Com and Moeller Medical, LLC support only those representations contained within the labeling of the Alpha-Stim® products.
.

Chronic Pain Relief Information For Pain Specialists and Medical Professionals